Erratum: Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting

Article Details

Authors
Martina Burlando, Riccardo Castelli, Emanuele Cozzani, Aurora Parodi

Article Type
Erratum

DOI
10.7573/dic.2021-6-8

Willingness of European healthcare workers to undergo vaccination against seasonal influenza: current situation and suggestions for improvement
Dermatologists’ attitude towards psoriasis treatment during the COVID-19 pandemic
Diagnosis and management of lentigo maligna: a review

Article Page

Abstract

The authors wish to make the following corrections to their article:

Burlando M, Castelli R, Cozzani E, Parodi A. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. Drugs in Context 2021; 10: 2021-2-6. DOI: 10.7573/dic.2021-2-6

Download free full text PDF

An open access, peer-reviewed journal focussing on the latest evidence and innovations in drug treatment across all therapeutic areas

Sign up for Article Alerts

Erratum: Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting

Article Details

Related Articles

Article Page

An open access, peer-reviewed journal focussing on the latest evidence and innovations in drug treatment across all therapeutic areas

Erratum: Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting

Article Details

Related Articles

Article Page

Loading..

Loading, Please Wait!